Treatment Sequencing and Line of Therapy for Biologics and <scp>JAK</scp> inhibitors in Rheumatoid Arthritis Patients: Implications for Design and Uptake of New Drugs and Predictive Biomarker Diagnostics

These findings highlight the size and characteristics of the eligible RA population in the U.S. initiating a new RA biologic or JAKi treatment each year, thus providing valuable insights for stakeholders developing or marketing new RA therapies or biomarker-based diagnostic tests to predict future treatment response.